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LipopolysaccharideOrchestration of the inﬂammatory response is crucial for clearing pathogens. Although theproduction ofmultiple
inﬂammatory cytokines has been thought to be regulated by common mechanisms, recent evidence indicates
that the expression of some cytokines is differentially regulated by epigenetic regulatory mechanisms. In this
study, we found that IL-6 production is selectively inhibited by the BET bromodomain protein (BRD) inhibitor
I-BET151 in RAW264.7 cells stimulated with lipopolysaccharide (LPS), whereas I-BET151 did not alter the pro-
duction of several other cytokines (TNFα, IL-1β and IL-10) at the concentration of IBET151 used. I-BET151
prevented the binding of CBP to the promoter of IL-6, but I-BET151 did not affect acetylation, phosphorylation,
nuclear translocation, or DNA binding of p65-NF-κB. In vivo, I-BET151 treatment in the experimental autoim-
mune encephalomyelitis mouse model of multiple sclerosis decreased the early clinical symptoms, which are
thought to be dependent on cytokine production. Altogether, these data suggest that targeting epigenetic-
related proteins, such as BET proteins, may provide a strategy to reduce inﬂammation and the severity of inﬂam-
matory diseases, such as multiple sclerosis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The inﬂammatory response to pathogens involves the orchestrat-
ed expression of multiple genes encoding inﬂammatory and anti-
inﬂammatory proteins, which is critical to eliminate pathogens.
Regulation of the timing and amplitude of increased expression of in-
ﬂammatory genes is vital for an efﬁcient immune defense. Therefore,
precise regulation of the nuclear chromatin complexes present on the
promoters of each inﬂammatory gene is critical. Acetylation of histones
is considered to be among the most important regulatory triggers for
controlling the open and closed state of the chromatin. Recently, a family
of acetylation mark “reader” proteins that includes BET bromodomain
proteins (BET proteins; e.g., BRD2, BRD3 and BRD4), has been shown to
govern the assembly of histone acetylation-dependent chromatin com-
plexes that regulate inﬂammatory gene expression [7,12,13,22]. Some
of the actions of BET proteins have been identiﬁed through the use ofnterleukin 1β; IL-6, interleukin-
ne encephalomyelitis; ELISA,
charide; NF-κB, nuclear factor
immunoprecipitation
try and Biochemistry, Gautier
of Medicine, Miami, FL 33136.newly designed small molecules that act as histone mimics, which dis-
place BET proteins from acetylated histones and alter the transcriptional
landscape [3–5,15,24]. These small molecule inhibitors are speciﬁc for
BRD2, BRD3, BRD4, and BRDT, and generally do not inhibit other epige-
netic enzymes [3–5,15,16,24]. Among the most potent and selective
BET protein inhibitors is I-BET151, which preferentially inhibits BRD4
(KD= 50 nM) [14,18]. I-BET151 has beenwell characterized particularly
in models of dysregulated transcription, such as in cancer, and been
suggested to control the inﬂammatory response [15].
Pro-inﬂammatory cytokines, such as interleukin-6 (IL-6) and tumor
necrosis factor-α (TNFα), are induced in response to many pathogens,
as well as experimentally by lipopolysaccharide (LPS). The induction
of these proinﬂammatory cytokines is required for the initial innate
immune response, but the prolonged expression of these cytokines
can have a deleterious effect on the host. Therefore, understanding
the mechanisms regulating cytokine transcription may lead to novel
treatments for chronic inﬂammation and inﬂammatory diseases. Most
pro-inﬂammatory cytokines induced by LPS require the activation of
NF-κB. NF-κB is activated by phosphorylation,which promotes its trans-
location to the nucleus, and acetylation of NF-κB has been shown to en-
hance its transcriptional activity [20]. Because BRD4 associates with
acetylated NF-κB, we tested the hypothesis that I-BET151, which binds
in the BRD4-acetyl-lysine-binding pocket, could selectively modulate
the expression of some NF-κB dependent pro-inﬂammatory genes,
and that this confers a certain selectivity to the action of NF-κB.
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2.1. Reagents
Protein-free Escherichia coli (K235) LPS was prepared as described
[8]. I-BET-151 (GSK1210151A) was synthesized to N99.5% purity as
described [3].
2.2. Cell culture
RAW264.7 cells were cultured in DMEM medium supplemented
with 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL
streptomycin. In order to test if BRD4 inhibition attenuates IL-6 produc-
tion, the cells were treated with LPS (100 ng/mL), I-BET151 (1–60 μM),
or both, in cell culturemediumwithout supplements for 30min to 24 h
before cells were harvested for analyses.
2.3. Immunoprecipitation and immunoblotting
For immunoblotting, cellswere lysedwith a triton lysis buffer (20mM
Tris–HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 10%
glycerol) supplemented with protease and phosphatase inhibitors
(1 μg/mL leupeptin, aprotinin, pepstatin A, 1 mM orthovanadate,
50 mM NaF, 0.1 μM okadaic acid, 1 mM PMSF). Nuclear and cytosolic
fractions were prepared using a nuclear extraction kit (Active Motif).
Protein concentrations were evaluated by the Bradford assay. Proteins
were resolved with SDS-PAGE and transferred to nitrocellulose mem-
branes, which were immunoblotted with antibodies to phospho-
Ser536-p65, acetyl-Lys310-p65, CREB (Cell Signaling Technology), p65
(Rockland), BDR4 (Santa Cruz), or β-actin (Sigma). For immunoprecip-
itation, cell extracts were incubated with the indicated primary anti-
body overnight at 4 °C with gentle agitation, followed by incubation
with protein A or G sepharose beads (Amersham) for 2 h at 4 °C. The
precipitated immune complexeswerewashed three times and Laemmli
buffer was added to the samples before resolving the proteins on
SDS-PAGE gels as described above.
2.4. p65 DNA binding
To test if I-BET151 treatment affected the DNA binding activity of
p65 NF-κB, nuclei from RAW264.7 cells treated with LPS (100 ng/mL),
I-BET151 (1 μM), or both, were isolated with a nuclear extraction kit
according to the manufacturer's instructions (Active Motif). Nuclear
proteins (100 μg) from RAW264.7 cells were incubated with a p65 con-
sensus oligonucleotide bound to a 96 well-plate to determine the DNA
binding activity of p65 NF-κB (Active Motif) according to the
manufacturer's instructions.
2.5. Measurement of cytokines
Mouse IL-6, IL-1β, IL-10 and TNFα in RAW264.7 cell culture superna-
tants diluted 10-fold were measured with an enzyme-linked immuno-
sorbent assay (ELISA) kit (eBioscience) according to the manufacturer's
instructions.
2.6. Viability
Cell viability was assessed by a colorimetric 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A multi-well
scanner was used to measure the absorbance at 570–630 nm dual
wavelengths.
2.7. Chromatin immunoprecipitation (ChIP)
To identify proteins bound to the IL-6 promoter, nuclei from cross-
linked RAW264.7 cells were resuspended in Tris–EDTA buffer andsonicated. The soluble chromatin was adjusted into immunoprecipita-
tion assay (RIPA) buffer (0.1% sodium dodecyl sulfate, 1% Triton X-
100, 0.1% sodium deoxycholate, 140 mM NaCl) and precleared. Immu-
noprecipitation was performed with 1 μL of anti-p65 (Rockland), 2 μL
of anti-acetylated p65 (Cell Signaling), 10 μL of anti-BRD4 (Santa
Cruz), 10 μL of anti-CBP (Santa Cruz), or 2 μL of anti-IgG (Cell Signaling)
and the immune complexes were absorbed with protein A beads
(Millipore) blocked with bovine serum albumin and salmon sperm
DNA. Immunoprecipitated DNA was subjected to semiquantitative
PCR. The PCR productswere resolved in 2.0% agarose gels in 1× Tris/bo-
rate/EDTA buffer, and the gels were stained with ethidium bromide. Q-
PCR was used to quantify the ChIP results, and all results were normal-
ized by the respective input values. The IgG control was run in parallel
to assure no unspeciﬁc binding to the promoter of IL-6. The mouse IL-
6 promoter was analyzed using primers: IL-6 forward 5′-AAG CAC
ACT TTC C CC TTC C-3′, and reverse, 5′-CTA TCG TTC TTGGTGGGC TC-3′.2.8. EAE induction
Mice were injected intraperitoneally (ip) with 3 mg/kg I-BET151
starting 3 days prior to immunization and then daily throughout the ex-
periment. EAE was induced in male C57Bl/6 mice with subcutaneous
(s.c.) injection of 50 μg MOG35–55 peptide emulsiﬁed in complete
Freund's adjuvant containing 1.5 mg/mL heat-killedMycobacterium tu-
berculosis H37Ra (Difco Laboratories). On the day of immunization and
48 h later, mice were injected ip with 50 ng of pertussis toxin in PBS.
Mice were examined daily for clinical signs of EAE. Mice were assigned
clinical symptom scores as follows: 0, no paralysis; 1, loss of tail tone; 2,
ﬂaccid tail; 3, incomplete paralysis of one or two hind legs; 4, complete
hind limb paralysis; 5, moribund (animals were humanly euthanized);
6, death. To compare the time course of disease development in differ-
ent groups ofmice, thedaily average of the clinical scoreswas calculated
for each group.2.9. Statistical analysis
Data are expressed asmeans± SEM. Statistical signiﬁcance between
groups was evaluated by Mann Whitney or ANOVA tests. Differences
between groups were considered signiﬁcant at p b 0.05.3. Results
3.1. I-BET151 preferentially reduces IL-6 production induced by LPS in
RAW267.4 cells
I-BET was reported to downregulate speciﬁcally the expression of
151 inﬂammatory geneswhile increasing the expression of 5 inﬂamma-
tory genes in response to LPS in bone marrow-derived macrophages
[15], showing that reader proteins can confer a certain selectivity in
regulating gene expression. Consistent with this, examination of pro-
inﬂammatory cytokines in macrophage-like RAW264.7 cells showed
that 1 μM I-BET151 preferentially inhibited the production of IL-6 in re-
sponse to LPS at both 6 and 24 h (Fig. 1A), but had no effect on the pro-
duction of TNFα at the same times (Fig. 1B), or IL-1β at 24 h (Fig. 1C). In
contrast, increased concentrations of I-BET151 decreased TNFα produc-
tion (Fig. 1D) without affecting cell viability except for 60 μM I-BET151
(Fig. 1E). Reduced IL-6 production was not the consequence of upregu-
lated production of the anti-inﬂammatory cytokine IL-10, as the level of
IL-10 was unchanged by treatment with I-BET151 (Fig. 1F). Although
many pro-inﬂammatory genes have been shown to be dependent on
the activation of the transcription factor NF-κB, I-BET151 appears
to have a preferential regulatory effect on the production of the pro-
inﬂammatory IL-6 in response to LPS.
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Fig. 1. I-BET151 prevents IL-6 production in RAW264.7 cells. RAW264.7 cells were stimulated with 100 ng/mL LPS in serum-free medium, with or without 1 μM I-BET151, for 6 or 24 h,
as indicated. Supernatants were used to measure the production of IL-6 (A), TNFα (B), IL-1β (C) and IL-10 (F) by ELISA (n = 6; *p b 0.05 LPS treatment compared to untreated
samples, **p b 0.05 LPS + I-BET comparedwith samples treatedwith LPS, MannWhitney test). RAW264.7 cellswere stimulatedwith 100 ng/mL LPS in serum-freemedium,with orwith-
out 1, 3, 6, 10, 30, or 60 μM I-BET151, for 6 h. Supernatantswere used tomeasure the production of TNFα (D) by ELISA, and cell viability wasmeasured by theMTT assay (F) (n=3; *p b 0.05
LPS treatment compared to I-BET151-treated samples, one-way ANOVA, Bonferroni post-hoc test).
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In response to LPS treatment, p65-NF-κB is phosphorylated and
translocates to the nucleus to induce the expression of many pro-
inﬂammatory genes. The level of phospho-Ser536-p65 in RAW264.7
cells was increased by LPS treatment, and remained unchanged in the
presence of I-BET151 (Fig. 2A). In addition, I-BET151 did not alter either
the nuclear translocation of p65, or the nuclear phosphorylation of p65
(Fig. 2B). Acetylation of p65 on Lysine 310, which is critical for the acti-
vation of NF-κB in the inﬂammatory response [6,10,11], was also unal-
tered in the presence of I-BET151, both in whole cell extracts and in
the nuclear fraction (Fig. 2AB). Altogether, these results demonstrate
that I-BET151 did not impair the activation and the translocation of
p65 to the nucleus, suggesting that the regulation of IL-6 production
by I-BET151 occurs at the transcriptional level.
3.3. I-BET151 reduces the association between BRD4 and acetylated p65
In order to decipher the speciﬁc role of I-BET151 in the NF-κB-
dependent regulation of IL-6 expression, we also examined if I-BET151modulates the binding of BRD4with NF-κB. Acetylation provides specif-
ic docking sites for bromodomain proteins, and acetylation of lysines in
particular are thought to regulate the functional interactions of proteins
with a bromodomain protein [19,21]. It has been shown that BRD4
associates with acetylated NF-κB, and that BRD4 is recruited to the pro-
moters of a subset of NF-κB target genes [9]. In RAW264.7 cells, treat-
ment with I-BET151 did not alter the association of BRD4 with p65
after stimulation with LPS (Fig. 3B). However, there was an increased
association of BRD4 with acetyl-Lys310-p65 after treatment with LPS,
and this was abolished by I-BET151 treatment (Fig. 3A). These results
indicate that inhibition of BRD4 by I-BET151 prevents BRD4 association
with the transcriptionally active acetylated form of p65.
3.4. I-BET151 did not alter the binding of p65 to a DNA consensus sequence
but restored acetylated p65 binding to the promoter of IL-6 in response
to LPS
We measured the DNA binding activity of p65 in response to treat-
ment with I-BET151 and LPS to determine if impairment of this process
may underlie the mechanism of action of I-BET151 in the selective
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Fig. 2. I-BET151 does not affect phosphorylation or acetylation of p65. RAW264.7 cells were stimulated with 100 ng/mL LPS in serum free medium, with or without 1 μM I-BET151, for
30 min and cell lysates (A) and nuclear extracts (B) were immunoblotted for phospho-Ser536-p65, acetyl-Lys310-p65, and total p65. β-actin (cell lysates) or CREB (nuclear extracts)
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1552 E. Barrett et al. / Biochimica et Biophysica Acta 1842 (2014) 1549–1555regulation of IL-6 production. The LPS-induced increase in the binding
of p65 to an oligonucleotide consensus sequence and the binding of
p65 to the promoter of IL-6 was unaltered by I-BET151 treatment after
stimulation with LPS (Fig. 4A). LPS reduced acetylated p65 binding to
the promoter of IL-6, and this was blocked by I-BET151 treatment
(Fig. 4C). LPS also reduced BRD4 binding to the IL-6 promoter, and this
was reversed by I-BET151 treatment (Fig. 4D). These results show that
I-BET151 lead to the restoration of acetylation of p65 on the promoter
of IL-6 and therefore the binding of BRD4 in the IL-6 promoter
(Fig. 4D). LPS also promoted CBP recruitment to the IL-6 promoter,
and I-BET151 blocked this recruitment (Fig. 4E). Immunoprecipitation
with a non-speciﬁc IgG did not pull down any DNA covering the IL-6
promoter region, as we were unable to amplify any DNA by Q-PCR
(Fig. 4F). Altogether, these results show that I-BET151 blocks the
LPS-induced decrease of acetylated p65 in the promoter of IL-6 by pro-
moting BRD4 binding rather than CBP binding to the IL-6 promoter.
3.5. I-BET151 delays onset of EAE in mice
Because I-BET151 appears to be a critical regulator of the proinﬂam-
matory cytokine IL-6, we also tested if I-BET151 administration has a
beneﬁcial effect in a chronic model of inﬂammation involving IL-6,
experimental autoimmune encephalomyelitis (EAE), which is widelyused as a model of multiple sclerosis. Mice were pretreated before im-
munization with I-BET151 for 3 days, and daily after immunization
throughout the development of EAE. Mice treated with I-BET151 had a
signiﬁcant delay in the onset of clinical symptoms and attenuated the
maximal severity of EAE (Fig. 5). This result demonstrates that targeting
chronic inﬂammation by I-BET151 is beneﬁcial in the development of
EAE.
4. Discussion
Cytokines are critical mediators of immune responses. The duration
and amplitude of their production are tightly regulated, because either
excess or insufﬁcient cytokine production can have detrimental conse-
quences in the clearance of pathogens or the health of the host. The ex-
pression of cytokines is likely regulated predominantly at the level of
transcription factors. In particular, NF-κB is considered themaster regu-
lator of the production ofmultiple inﬂammatory cytokines, especially in
response to LPS stimulation [20]. Recently, another level of regulation
has been uncovered that involves epigenetic tuning of cytokine
production.
Herewe report that a bromodomain protein inhibitor (I-BET151) se-
lectively blocks the production of IL-6, without affecting the production
of two other pro-inﬂammatory cytokines (TNFα, IL-1β) or the anti-
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inhibited by I-BET151 are selectively involved in the control of the pro-
duction of IL-6. This is partially in agreement with the results recently0
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due to the concentration of inhibitors used, and we conﬁrmed that
higher concentrations of I-BET151 reduce the production of TNFα
(Fig. 1D). Similarly, the production of IL-1βmay be reducedwith higher
concentrations of I-BET151, consistent with the ﬁndings of [15] where
IL-1βwas reduced by I-BET151. It is likely that other cytokines in addi-
tion to IL-6 may also be regulated by high concentrations of I-BET151.
Although BRD proteins are thought to regulate histone acetylation-
dependent complexes, it appears that they carry a certain speciﬁcity in
their mechanism of action since they are able to modulate speciﬁc
promoters [17]. However, the mode of selectivity of these BRD proteins
remains to be determined.
Here we report that treatment with I-BET151 decreased the binding
of CBP, which has been shown to be required for the action of NF-κB in
the production of IL-6, as well as other cytokines, suggesting the possi-
bility that the binding of BRD4 to the promoter of IL-6 prevents the
binding of CBP. We found that I-BET151 decreases the binding of
BRD4 to acetylated NF-κB, suggesting that BRD4 is required for the
proper recruitment of transcriptional machinery to acetylated NF-κB.
This is consistent with the ﬁndings of [9] showing that in response
to TNFα stimulation, BRD4 is recruited to the promoter by acetylated
NF-κB. This is also consistent with the ﬁnding by [2] that BRD4 is teth-
ered to the transcription complex through NF-κB. Other proteins may
also be involved in this transcriptional complex, as we hypothesize
that BRD4 binding to acetylated NF-κB in the promoter of IL-6 may in-
hibit recruitment of the transcriptional machinery to promote expres-
sion of IL-6 although additional data is required to test this hypothesis.
However, it remains to be determined which acetyltransferase is re-
sponsible for the acetylation of NF-κB on the promoter of IL-6 in the
presence of I-BET151. It will also be important to determine which
deacetylase reduces acetylation of NF-κB in the promoter of IL-6, be-
cause this deacetylasemay be also regulated by BRD4 andmay compete
with BRD4 for binding to the promoter of IL-6. These actions of I-BET151
may be particularly due to its interaction with BRD4, although it also
binds other BRD proteins, because as described in [2], BRD4 does not
bind to the promoter of TNFα, and we found no change in the produc-
tion of TNFα in the presence of I-BET151, suggesting that I-BET151
may preferentially regulate BRD4 to also inhibit IL-6 production. As
suggested by [23], signal transduction may also regulate the actions of
the BET proteins through kinase cascades.
Although many questions remain about the actions of BRD4 and
I-BET151, this study suggests that targeting BRD4 with I-BET151 is an
attractive therapeutic strategy [17] to dampen the production of IL-6
because I-BET151 nearly eliminates IL-6 production but does notblock the production of all NF-κB-dependent cytokines. But further ex-
periments using siRNA will be required to fully clarify the involvement
of BRD4 in the action of I-BET151. This potential therapeutic application
was further veriﬁed by examining the effects of long-term administra-
tion of I-BET151 in the mouse EAE model of multiple sclerosis. Admin-
istration of I-BET151 in the EAE model delayed onset of the disease,
which is thought to be highly dependent on cytokine production by
the innate immune system. Furthermore, I-BET151 was well-tolerated
by mice over a period of nearly 40 days of treatment. However, I-
BET151 administered at this dose was unable to prevent the disease
progression, suggesting that other pathogenic mechanisms in EAE
were not affected by I-BET151. These could include the production of
other cytokines, such as TNFα or IL-1β, that may have been unaffected
by I-BET151, or the activation of other immune cells. Nevertheless,
these results demonstrate a potential therapeutic advantage of using
I-BET151 in inﬂammatory diseases, in addition to LPS-induced endotox-
in shock or cancer [3–5,15,24], since EAE is a complex disease with an
unknown etiology and I-BET151 caused no apparent side effects during
the long-term chronic treatment. BET bromodomain protein inhibitors
were also shown to inhibit CD4+ T cell cytokine production [1], which
may also contribute to the EAE effects we observed.
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